

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

09/974,716

Applicant

Hua et al.

Filed

October 9, 2001

TC/A.U.

1621

Examiner

Sikarl A. Witherspoon

For

TRIPTYCENE ANALOGS

Docket No.

74-00

Customer No.:

23713

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for Express Mail in an envelope addressed to:

Commissioner for Patents.

PO Box 1450, Alexandria, VA 22313-1450

June 8, 2004

Confirmation No. 7851

Date

Cathy Nelson

EV 539737841 US Express Mail Tracking Number

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Further to the Information Disclosure Statement filed January 30, 2002, the Examiner is respectfully requested to consider the additional references, copies enclosed, which may qualify as prior art. For the Examiner's convenience, the references are listed on the attached Patent and Trademark Office Form PTO-1449.

References known to the applicants have been listed on PTO-1449. That information is cited in a spirit of forthrightness and cooperation to enable the applicants to obtain that measure of protection for the invention to which there is entitlement. However, no representation is made that the listed art actually qualifies as prior art under the patent statute and the mere use of PTO-1449 is not an admission that all listed references are prior art. No representation is made that applicants know of the best art.

06/14/2004 JBALINAN 00000134 09974716

01 FC:1806

180.00 GP

The relevance of references that are not in the English language is believed apparent from the structures described and shown therein.

This submission is accompanied by a check in the amount of \$180. If this amount is incorrect, please charge any deficiency or credit any overpayment to deposit account 07-1969.

Respectfully submitted,

Susan K. Doughty Reg. No. 43,595

GREENLEE, WINNER AND SULLIVAN, P.C.

5370 Manhattan Circle, Suite 201

Boulder, CO 80303

Telephone: (303) 499-8080 Facsimile: (303) 499-8089 E-mail: winner@greenwin.com

Attorney docket No. 74-00

June 8, 2004

Form PTO-1449		
ATTY DOCKET NO. 74-00	SERIAL NO. 09/974,716	FILING DATE October 9, 2001
APPAICANT: Hua et al.		GROUP 1621

#### **U.S. PATENT DOCUMENTS**

3	Es mr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
		5,958,970	9/28/99	Hua et al.	514	455	
	,						

### **FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Subclass	Translation Yes/No
WO 98/39010	9/11/98	WO	A61K 31/54	31/535	

**OTHER PRIOR ART** (including Author, Title, Date, Pertinent Pages, etc.)

OTH	IER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)
	P. Bartlett et al., Triptycene (9,10-o-Benzenoanthracene), J. Am. Chem. Soc. 64:2649-53, 1942
	P. Bedworth et al., The synthesis of a symmetrically substituted α-octa(isopentoxy)anthralocyanine, J. Chem. Soc. Chem. Commum. 1353-54, 1997
,	A. Begleiter et al., Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents, Cancer Res. 48:1727-35, 1988
	A. Brunmark et al., Redox and addition chemistry of quinoid compounds and its biological implications, Free Radical Biol. & Med. 7:435-477, 1989
	Criswell et al., Studies related to the conversion of 9,10-anthraquinones to anthracenes, J. Org. Chem. 39(6):770-774, 1974
	J. Daub et al., Chirale elektronentransfer-aktive chinone mit triptycenteilstrukturen: Synthesekonzeption und eigenschaften, Chem. Ber. 121:2187-2194, 1988
	A. Etienne, Dihydroxy-1.4 anthracene et derives alcoyles correspondants. Leur photooxydation et leur photodimerisation, Séance Du 1233-1235, 1955
	R. Ganapathi et al., Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells, Biochem. Pharmacology 40(7):1657-1662, 1990
	S. Ham et al., Studies on menadione as an inhibitor of the cdc25 phosphatase, Bioorg. Chem. 25:33-36, 1997
	D. Hamon et al., Reductive elimination of bromine from 2,3-disubstituted 1,4-dibromo-2-butenes by iodide ion: A convenient route to 2,3-bis[iodomethyl]-1,3-butadiene and related compounds, J. Chem. Soc. Chem. Comm. 873-874, November 1981

### **EXAMINER**

## DATE CONSIDERED

Form PTO-1449		. 1.7
ATTY DOCKET NO. 74-00	SERIAL NO. 09/974,716	FILING DATE October 9, 2001
APPLICANT: Hua et al.		GROUP 1621

	D. Hua, Syntheses of substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1.4.5.8-tetraones. Unusual reactives with amines, Abstract of poster presented at ACS 36 <sup>th</sup> Midwest Regional Meeting, Lincoln, Nebraska, October 10-13, 2001
	D. Hua et al., Syntheses and bioactivities of substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones. Unusual reactivities with amines, J. Org. Chem. 67:2907-2912, 2002
	D. Hua et al., A one-pot condensation of pyrones and enals. Synthesis of 1 <i>H</i> ,7 <i>H</i> -5a,6,8,9-tetrahydro-1-oxopyrano[4,3- <i>b</i> ][1]benzopyrans, J. Org. Chem. 62(20):6888-6896, 1997
	S. Hunig et al., 1,4,5,8-tetraoxo-1,4,5,8-tetrahydrothianthrene: synthesis, structure, and spectroelectrochemical properties, Chem. Ber. 126:465-471, 1992
	H. Iwamura et al., 5,8-dihydroxy-9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4-dione. An intramolecular triptycene quinhydrone, J. Chem. Soc. Chem. Comm. 16:720-721, 1978
	T. Jozefiak et al., Mixed-valence, conjugated semiquinones, J. Am. Chem. Soc. 111(11):4105-4106, 1989
	A. Kenani et al., Metal-complexing, DNA-binding and DNA-cleaving properties of a synthetic molecule AMBIGLU, a simplified model for the study of bleomycin, Eur. J. Med. Chem. 24:371-377, 1989
,	N. Krishnamachary et al., The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein, Cancer Res 53:3658-3661, 1993
	A. Lin et al., Potential bioreductive alkylating agents. 1. Benzoquinone derivatives, J. Med. Chem. 15(12):1247-1252, 1972
	A. Lin et al., Potential bioreductive alkylating agents. 2. Antitumor effect and biochemical studies of naphthoquinone derivatives, J. Med. Chem. 16(11):1268-1271, 1973
	A. Lin et al., Potential bioreductive alkylating agents. 3. Synthesis and antineoplastic activity of acetoxymethyl and corresponding ethyl carbamate derivatives of benzoquinones, J. Med. Chem. 17(5):558-561, 1974
	A. Lin et al., Potential bioreductive alkylating agents. 5. Antineoplastic activity of quinoline-5,8-diones, naphthazarins, and naphthoquinones, J. Med. Chem. 18(9):917-921, 1975
	Y-H. Ling et al., Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells, Cancer Res. 53:1845-1852, 1993

## DATE CONSIDERED

Form PTO-1449		
ATTY DOCKET NO. 74-00	SERIAL NO. 09/974,716	FILING DATE October 9, 2001
APPLICANT: Hua et al.		GROUP 1621

E. Lipczynska-Kochany et al., Charge-transfer complexation with a new class of electron acceptors made of triptycenequinone unit, Chemistry Letters 7:1075-1078, 1982
L. Liu, DNA topoisomerase poisons as antitumor drugs, Ann. Rev. Biochem. 58:351-375, 1989
T. McGrath et al., Adriamycin resistance in HL60 cells in the absence of detectable P-glygoprotein, Biochem. Biophys. Res. Comm. 145(3):1171-1176, 1987
T. McGrath et al., Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of <i>mdr</i> gene expression, Biochem. Pharmacol. 38(20):3611-3619, 1989
W. Marsh et al., Relation and characterization of Adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug, Cancer Res. 46:4053-4057, 1986
W. Marsh et al., Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells, Cancer Res. 47:5080-5086, 1987
D. Marquardt et al., Mechanisms of multidrug resistance in HL60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein, Cancer Res. 50:1426-1430, 1990
D. Marquardt et al., Involvement of vacuolar H <sup>+</sup> -adenosine triphosphatase activity in multidrug resistance in HL60 cells, J. Natl. Cancer Inst. 83(15):1098-1102, 1991
E. Mimnaugh et al., Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei, Cancer Res. 45:3296-3304, 1985
H. Moore, Bioactivation as a model for drug design bioreductive alkylation, Science 197:527-532, 1977
T. Monks et al., Contemporary issues in toxicology. Quinone chemistry and toxicity, Toxicol. Appl. Pharmacol. 112:2-16, 1992
C. Myers et al., Anthracyclines. Chapter 14, In: <u>Cancer Chemotherapy:</u> <u>Principles and Practice</u> , B. Chabner et al. (eds), Lippincott, pp. 356-381, 1990
S. Newell et al., Tricyclic pyrone analogs: A new class of microtubule-disrupting anticancer drugs effective against murine leukemia cells in vitro, Int. J. Oncol. 12(2):433-442, 1998
S. Norvez, Liquid crystalline triptycene derivatives, J. Org. Chem. 58:2414-2418, 1993
P. O'Brien, Molecular mechanisms of quinone cytotoxicity, Chem-Biol. Interact. 80:1-41, 1991

## DATE CONSIDERED

Form PTO-1449			
ATTY DOCKET NO. 74-00	SERIAL NO. 09/974,716	FILING DATE October 9, 2001	
APPLICANT: Hua et al.		GROUP 1621	

	Γ.	TID: A 1 1 1 1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
	'	H. Patney, A general and simple route to the synthesis of triptycenes,
		Synthesis 694-696, September 1991
		E. Perchellet et al., Tricyclic pyrone analogs: A new synthetic class of
		bifunctional anticancer drugs that inhibit nucleoside transport, microtubule
		assembly, the viability of leukemic cells in vitro, and the growth of solid
	ļ	tumors in vivo, Anti-cancer Drugs 10(5):489-504, 1999
	ļ	E. Perchellet et al., Antitumor activity of tricyclic pyrone analogs, a new
		synthetic class of microtubule de-stabilizing agents, in the murine EMT-6
	1	mammary tumor cell line in vitro, Anti-Cancer Drugs 6(9):565-576, 1998
		JP. Perchellet et al., Triptycene analogs: A novel synthetic class of
		bifunctional anticancer drugs effective in the nanomolar range in vitro,
		Introduction to Poster Presented at Am. Assoc. for Cancer Research 91 <sup>st</sup>
		Annual Meeting, San Francisco, CA, April 1-5, 2000
		JP. Perchellet et al., Triptycene analogs: A novel synthetic class of
		bifunctional anticancer drugs effective in the nanomolar range in vitro,
		Abstract of Poster Presented at Am. Assoc. for Cancer Research 91 <sup>st</sup> Annual
		Meeting, San Francisco, CA, April 1-5, 2000
<u> </u>		JP. Perchellet et al., Triptycene analogs: A novel synthetic class of
		bifunctional anticancer drugs effective in the nanomolar range in vitro,
		Proceedings of the American Association for Cancer Research 41:602, March
		2000
		JP. Perchellet et al., Antitumor activity of novel tricyclic pyrone analogs in
		murine leukemia cells in vitro, Anticancer Research 17:2427-2434, April 1997
	<del>                                     </del>	XB. Qiu et al., Anticancer quinones induce pRb-preventable G2/M cell cycle
	1	arrest and apoptosis, Free Radical Biol. & Med. 24(5):848-854, 1998
	<del> </del>	H. Quast et al., ESR-spektroskopischer nachweis intramolekularer
		wechselwirkungen in radikalkationen von poly(α-methoxy)triptycenen, Chem.
		Ber. 119:1016-1038, 1986
	†	H. Quast et al., Intramolekulare wechselwirkungen in radikalkationen von di-
		und tetra(α-methoxy)-9,10-dihydro-9,10-ethanoanthracenen, Chem. Ber.
		119:2414-2429, 1986
	†	C. Ramachandran et al., Bcl-2 and mdr-1 gene expression during doxorubicin-
	′	induced apoptosis in murine leukemic P388 and P388/R84 cells, Anticancer
		Research 17:3369-3376, 1997
	<u> </u>	L. Rossi et al., Quinone toxicity in hepatocytes without oxidative stress, Arch.
		Biochem. Biophys. 251:25-35, 1986
		G. Russell et al., Radical anions of triptycene bis- and tris(quinones), J. Am.
		Chem. Soc. 103(6):1560-1561, 1981
		V. Skvarchenko et al., Advances in the chemistry of triptycene, Russ. Chem.
	,	Rev. 43(11):951-966, 1974
ــــــــــــــــــــــــــــــــــــــ	<del></del>	

## DATE CONSIDERED

Form PTO-1449		
ATTY DOCKET NO. 74-00	SERIAL NO. 09/974,716	FILING DATE October 9, 2001
APPLICANT: Hua et al.		GROUP 1621

,	B. Wang et al., A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines, Int. J. Oncology 19:1169-1178, 2001
	B. Wang et al., Antitumor triptycene bisquinones: A novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities, Anti-Cancer Drugs 14:503-514, 2003
	Y. Wang et al., Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines, Cancer Letters 188:73-83, 2002

# DATE CONSIDERED